ArticleFrontiers in cellular and infection microbiology2026
Population-level and longitudinal MIC distributions for antimicrobials against drug-resistant
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant tuberculosis (DR-TB) remains a significant global health challenge, with increasing resistance to both first- and second-line anti-tuberculosis drugs. Understanding the demographic distribution, temporal trends, and resistance profiles of DR-TB is essential for improving treatment strategies and public health interventions. Objective: This study aimed to examine the demographic characteristics, temporal distribution, and minimum inhibitory concentration (MIC) patterns of drug-resistant Methods: A total of 402 drug-resistant Results: The majority of patients were male (72.14%), and the most common form of DR-TB was isoniazid-resistant TB (23.14%). The study found significant seasonal variation, with higher DR-TB incidence in winter and spring months, and the temporal distribution was affected by COVID-19. Resistance rates were highest for isoniazid (40.30%), cycloserine (47.76%), and para-aminosalicylic acid (52.24%). Across the DR-TB cohorts, MICs for isoniazid, ethionamide, para-aminosalicylic acid, and amikacin demonstrated a significant upward trend, whereas a declining pattern was observed for ethambutol. The longitudinal comparison of paired Conclusion: This study highlights the increasing burden of DR-TB, with increasing MICs and relatively high resistance rates for a few key drugs indicating reduced drug susceptibility over time. The increasing MICs highlight the need for continuous resistance monitoring and enhanced DR-TB control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.